GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Assembly Biosciences Inc (FRA:V7B) » Definitions » Earnings per Share (Diluted)

Assembly Biosciences (FRA:V7B) Earnings per Share (Diluted) : €-6.35 (TTM As of Sep. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Assembly Biosciences Earnings per Share (Diluted)?

Assembly Biosciences's Earnings per Share (Diluted) for the three months ended in Sep. 2024 was €-1.36. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 was €-6.35.

Assembly Biosciences's EPS (Basic) for the three months ended in Sep. 2024 was €-1.36. Its EPS (Basic) for the trailing twelve months (TTM) ended in Sep. 2024 was €-6.35.

Assembly Biosciences's EPS without NRI for the three months ended in Sep. 2024 was €-1.36. Its EPS without NRI for the trailing twelve months (TTM) ended in Sep. 2024 was €-6.35.

During the past 3 years, the average EPS without NRIGrowth Rate was 14.00% per year. During the past 5 years, the average EPS without NRI Growth Rate was 20.80% per year. During the past 10 years, the average EPS without NRI Growth Rate was 8.40% per year.

During the past 13 years, Assembly Biosciences's highest 3-Year average EPS without NRI Growth Rate was 65.60% per year. The lowest was -30.10% per year. And the median was 19.80% per year.


Assembly Biosciences Earnings per Share (Diluted) Historical Data

The historical data trend for Assembly Biosciences's Earnings per Share (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Assembly Biosciences Earnings per Share (Diluted) Chart

Assembly Biosciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Earnings per Share (Diluted)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -40.18 -17.26 -31.86 -21.79 -12.27

Assembly Biosciences Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Earnings per Share (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.08 -1.62 -1.53 -1.84 -1.36

Competitive Comparison of Assembly Biosciences's Earnings per Share (Diluted)

For the Biotechnology subindustry, Assembly Biosciences's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Assembly Biosciences's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Assembly Biosciences's PE Ratio distribution charts can be found below:

* The bar in red indicates where Assembly Biosciences's PE Ratio falls into.



Assembly Biosciences Earnings per Share (Diluted) Calculation

Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.

Assembly Biosciences's Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2023 is calculated as

Diluted Earnings Per Share (A: Dec. 2023 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-56.146-0)/4.577
=-12.27

Assembly Biosciences's Earnings Per Share (Diluted) for the quarter that ended in Sep. 2024 is calculated as

Diluted Earnings Per Share (Q: Sep. 2024 )=(Net Income - Preferred Dividends / Shares Outstanding (Diluted Average)
=(-8.661-0)/6.351
=-1.36

Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-6.35

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.


Assembly Biosciences  (FRA:V7B) Earnings per Share (Diluted) Explanation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Assembly Biosciences Earnings per Share (Diluted) Related Terms

Thank you for viewing the detailed overview of Assembly Biosciences's Earnings per Share (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Assembly Biosciences Business Description

Traded in Other Exchanges
Address
Two Tower Place, 7th Floor, South San Francisco, CA, USA, 94080
Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two innovative platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.

Assembly Biosciences Headlines

No Headlines